Pharmaceuticals

Enliven Therapeutics

Enliven Therapeutics released FY2026 Q1 earnings on May 7 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.38 (forecast USD -0.4516)

LifeSci Capital Maintains Buy Rating on Enliven Therapeutics

Enliven Therapeutics released FY2025 Annual Earnings on March 3 (EST), actual revenue USD 0 (forecast USD 10K), actual EPS USD -1.8299 (forecast USD -1.7328)

Enliven Therapeutics released FY2025 Q4 earnings on March 3 (EST), actual revenue USD 0 (forecast USD 10 K), actual EPS USD -0.4768 (forecast USD -0.3857)

Enliven Therapeutics' Leukemia Candidate ELVN-001 Shows Positive Clinical Trial Results

Enliven Therapeutics Inc. COO Reports Disposal of Common Stock

Enliven Therapeutics Reports Positive Phase 1b Results for Chronic Myeloid Leukemia Drug ELVN-001

Enliven Therapeutics, Inc. Receives Significant Funding

Candriam S.C.A. Invests in Enliven Therapeutics, Inc.

H.C. Wainwright Reiterates Buy Rating on Enliven Therapeutics

Enliven Therapeutics released FY2025 9 Months earnings on November 12 (EST), actual revenue USD 0, actual EPS USD -1.381

Enliven Therapeutics released FY2025 Q3 earnings on November 12, 2025 (EST), with actual revenue USD 0 (forecast USD 0) and actual EPS USD 0 (forecast USD -0.4362)

Syed Recommends Enliven Therapeutics Stock with a Buy Rating

Enliven Therapeutics to Present ELVN-001 Preliminary Clinical Data at ASH Annual Meeting

Analyst Roy Covers Healthcare Stocks

Enliven Therapeutics released FY2025 Semi-Annual earnings on August 13 (EST), actual revenue USD 0, actual EPS USD -1.0547

Enliven Therapeutics released FY2025 Q2 earnings on August 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.49 (forecast USD -0.5337)

Enliven Therapeutics Inc. CFO Reports Common Stock Disposition

Enliven Therapeutics COO Disposes of Common Stock

Enliven Therapeutics stock price rises, analysts upgrade rating

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

ELVN

Enliven Therapeutics CMO Helen Louise Collins sold 5,000 shares for approximately USD 39.53 to USD 41.21 after exercising stock options at USD 2.48 on May 18, 2026. Following the transactions, her reported holdings are 25,000 shares.

PUBT

Enliven CMO Helen Louise Collins sells USD 191,757 in common shares

Boris Peaker of JonesTrading has reiterated a Buy rating on ELVN-001, maintaining a $45 price target due to strong clinical data and strategic positioning. The drug shows promising molecular response rates and tolerability in late-line CML patients. Peaker highlights ELVN-001's unique mechanism and efficacy compared to competitors, alongside the company's solid cash position. Guggenheim also initiated coverage with a Buy rating and a $80 price target. Peaker has a 20.3% average return and a 45.78% success rate on his stock recommendations.

Tip Ranks

Relay Therapeutics

Nuvation Bio

NUVATION BIO INC C/WTS 10/02/2026 (TO PUR COM)

Boris Peaker Reiterates Buy Rating on ELVN-001 with Unchanged $45 Price Target, Citing Strong Clinical Data and Strategic Positioning

Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML | ELVN Stock News

StockTitan

Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML | ELVN Stock News

ARKG

Needham analyst Boris Peaker has reiterated a Buy rating on Enliven's ELVN stock, citing strong efficacy of ELVN-001 in chronic myeloid leukemia (CML) compared to existing therapies. He highlights significant early Phase 1 data and upcoming catalysts, including additional Phase 1 data in mid-2026 and the pivotal Phase 3 ENABLE-2 trial starting in late 2026. Peaker views Enliven as a strategic asset, especially after Merck's acquisition of a competitor, positioning it well for potential takeover opportunities. Clear Street also maintains a Buy rating with a $55 price target.

iShares US Pharma

Ark Genomic Revolution ETF

Direxion S&P Biotech Bull 3X

Health Care Select Sector SPDR

iShares Global Healthcare

iShares Biotechnology ETF

SPDR S&P Biotech

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

VG Health

ALPS Medical Breakthrough

Merck

Needham’s Boris Peaker Reiterates Buy on Enliven, Citing Strong ELVN-001 Efficacy in CML and Pivotal Phase 3 ENABLE-2 Catalyst Pathway

Earnings Watch

Enliven Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

Enliven Therapeutics, Inc. (Nasdaq: ELVN) reported its first quarter financial results for 2026, highlighting a strong cash position of $452 million, expected to last until mid-2029. The company is preparing to initiate the Phase 3 ENABLE-2 trial for ELVN-001 in the second half of 2026, following positive Phase 1b data. R&D expenses decreased to $20.7 million, while G&A expenses rose to $7.1 million, resulting in a net loss of $23.6 million. Enliven aims to address unmet needs in chronic myeloid leukemia with its innovative therapies.

prnewswire

16:05 ETEnliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

Enliven Therapeutics(ELVN.US)

Enliven CMO Helen Louise Collins sells USD 191,757 in common shares

Boris Peaker Reiterates Buy Rating on ELVN-001 with Unchanged $45 Price Target, Citing Strong Clinical Data and Strategic Positioning

Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML | ELVN Stock News

Needham’s Boris Peaker Reiterates Buy on Enliven, Citing Strong ELVN-001 Efficacy in CML and Pivotal Phase 3 ENABLE-2 Catalyst Pathway

Enliven Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

16:05 ETEnliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update